Antineoplastic Combined Chemotherapy Protocols
"Antineoplastic Combined Chemotherapy Protocols" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
| Descriptor ID |
D000971
|
| MeSH Number(s) |
E02.183.750.500 E02.319.077.500 E02.319.310.037
|
| Concept/Terms |
Antineoplastic Combined Chemotherapy Protocols- Antineoplastic Combined Chemotherapy Protocols
- Combined Antineoplastic Agents
- Antineoplastic Agents, Combined
- Agent, Combined Antineoplastic
- Agents, Combined Antineoplastic
- Antineoplastic Agent, Combined
- Combined Antineoplastic Agent
- Antineoplastic Combined Chemotherapy Regimens
- Drug Combinations, Antineoplastic
- Anticancer Drug Combinations
- Anticancer Drug Combination
- Drug Combination, Anticancer
- Drug Combinations, Anticancer
- Antineoplastic Drug Combinations
- Antineoplastic Drug Combination
- Combinations, Antineoplastic Drug
- Drug Combination, Antineoplastic
Antineoplastic Chemotherapy Protocols- Antineoplastic Chemotherapy Protocols
- Antineoplastic Chemotherapy Protocol
- Chemotherapy Protocol, Antineoplastic
- Protocol, Antineoplastic Chemotherapy
- Protocols, Antineoplastic Chemotherapy
- Cancer Chemotherapy Protocols
- Cancer Chemotherapy Protocol
- Chemotherapy Protocol, Cancer
- Chemotherapy Protocols, Cancer
- Protocol, Cancer Chemotherapy
- Protocols, Cancer Chemotherapy
- Chemotherapy Protocols, Antineoplastic
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Combined Chemotherapy Protocols".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Combined Chemotherapy Protocols".
This graph shows the total number of publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in this website by year, and whether "Antineoplastic Combined Chemotherapy Protocols" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 9 | 3 | 12 |
| 1996 | 10 | 4 | 14 |
| 1997 | 7 | 1 | 8 |
| 1998 | 12 | 3 | 15 |
| 1999 | 9 | 3 | 12 |
| 2000 | 8 | 3 | 11 |
| 2001 | 5 | 3 | 8 |
| 2002 | 8 | 7 | 15 |
| 2003 | 8 | 11 | 19 |
| 2004 | 7 | 8 | 15 |
| 2005 | 11 | 6 | 17 |
| 2006 | 14 | 7 | 21 |
| 2007 | 16 | 5 | 21 |
| 2008 | 24 | 8 | 32 |
| 2009 | 19 | 8 | 27 |
| 2010 | 19 | 11 | 30 |
| 2011 | 20 | 13 | 33 |
| 2012 | 16 | 6 | 22 |
| 2013 | 23 | 6 | 29 |
| 2014 | 31 | 12 | 43 |
| 2015 | 25 | 14 | 39 |
| 2016 | 13 | 14 | 27 |
| 2017 | 22 | 16 | 38 |
| 2018 | 33 | 17 | 50 |
| 2019 | 30 | 12 | 42 |
| 2020 | 26 | 18 | 44 |
| 2021 | 16 | 27 | 43 |
| 2022 | 9 | 34 | 43 |
| 2023 | 3 | 37 | 40 |
| 2024 | 21 | 23 | 44 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antineoplastic Combined Chemotherapy Protocols" by people in Profiles.
-
Treatment patterns and outcomes in follicular lymphoma with POD24: an analysis from the LEO Consortium. Blood Adv. 2025 Mar 11; 9(5):1013-1023.
-
Long-term survival can be achieved in a significant fraction of older patients with core-binding factor acute myeloid leukemia treated with intensive chemotherapy. Haematologica. 2025 Mar 01; 110(3):608-620.
-
Impact of measurable residual disease clearance kinetics in patients with AML undergoing intensive chemotherapy. Blood Adv. 2025 Feb 25; 9(4):783-792.
-
Venetoclax plus low-intensity chemotherapy for adults with acute lymphoblastic leukemia. Blood Adv. 2025 Feb 11; 9(3):617-626.
-
Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML. Blood. 2025 Feb 06; 145(6):612-624.
-
Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas. Clin Cancer Res. 2025 Feb 03; 31(3):479-490.
-
Phase II Trial of Induction Chemotherapy for Advanced Sinonasal Squamous Cell Carcinoma. Clin Cancer Res. 2025 Jan 17; 31(2):258-265.
-
Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma. Blood. 2025 Jan 16; 145(3):290-299.
-
Treatment of focal anaplastic Wilms tumor: A report from the Children's Oncology Group AREN0321 and AREN03B2 studies. Cancer. 2025 Jan 15; 131(2):e35713.
-
Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study. Leukemia. 2025 Mar; 39(3):710-719.